SUBSCRIBE
SUBSCRIBE
News   Drug Development

Eli Lilly and Company, Merck KGaA Erbitux Fails to Stop Colon Cancer Before It Spreads

June 7, 2010 | 
1 min read
Bloomberg -- Eli Lilly & Co. and Merck KGaA’s Erbitux, approved for advanced colon cancer, failed to slow tumors in a study designed to expand the medicine’s use to patients whose disease is in an earlier stage.
Clinical research Postmarket research
Eli Lilly and Company
MORE ON THIS TOPIC
Biotechnology and molecular genetic engineering. 3D illustration of science and molecular technology.
Duchenne muscular dystrophy
Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment
January 26, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Set your goals is shown using the collage with aim and the hand. Business targeting, aiming, focus concept and way to achieve a goal
Ovarian cancer
Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie
January 26, 2026
 · 
2 min read
 · 
Tristan Manalac
Pros and cons collage. Mixed media thumbs up and thumbs down hand gestures with speech bubbles. Review concept, positive and negative feedback vector illustration.
Immunology and inflammation
Sanofi Stumbles Again in Eczema—But Plans FDA Filing for OX40 Blocker Anyway
January 23, 2026
 · 
2 min read
 · 
Tristan Manalac
Start early or business advantage. Businessman starts running ahead of competitors vector
Pain
Lexicon Opens Path to $1B+ Opportunity as FDA Greenlights Phase III for Non-Opioid Pill
January 22, 2026
 · 
2 min read
 · 
Tristan Manalac